Skip to main content
Erschienen in:

25.11.2021 | Original Contributions

Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery

verfasst von: Thom Kok, Hans de Boer, Bart Witteman, Marcel Hovens, Matthijs van Luin, Houshang Monajemi

Erschienen in: Obesity Surgery | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite limited evidence about the efficacy and safety of anticoagulation in patients post bariatric surgery, both vitamin K antagonists (VKA) and direct-acting oral anticoagulants (DOACs) are commonly prescribed.

Aim

To evaluate plasma anti-Xa levels of DOACs in morbidly obese (MO) patients before and after a Roux-en-Y gastric bypass (RYGB) procedure.

Patients and Methods

Retrospective, cross-sectional, and longitudinal study of anti-Xa activity of apixaban or rivaroxaban in MO patients (N = 41).

Results

Preoperative analysis of plasma anti-Xa levels were within the normal range in patients using apixaban (n = 29; body mass index [BMI] 44.5 ± 5.1 kg/m2) as well as those using rivaroxaban (n = 12; BMI 42.6 ± 5.9 kg/m2). Postoperative anti-Xa levels of apixaban were all within the therapeutic range, whereas anti-Xa levels of rivaroxaban were subtherapeutic in nine out of 14 (64%) patients. Perioperative longitudinal follow-up in patients using apixaban (n = 18) showed no significant change in anti-Xa levels after RYGB.

Conclusion

Plasma anti-Xa levels of apixaban in MO patients remained within the therapeutic range up to a body weight of 144 kg. In patients using rivaroxaban, no statistically significant relation between anti-Xa levels and bodyweight was found. After RYGB, plasma anti-Xa levels of apixaban were unaffected, whereas plasma anti-Xa levels of rivaroxaban tended to become subtherapeutic.
Literatur
1.
Zurück zum Zitat Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythm Electrophysiol Rev. 2019;8(1):28–36.CrossRef Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythm Electrophysiol Rev. 2019;8(1):28–36.CrossRef
2.
Zurück zum Zitat Ibáñez L, Sabaté M, Vidal X, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): a cross-national drug utilization study. Br J Clin Pharmacol. 2019;85(11):2524–39.CrossRef Ibáñez L, Sabaté M, Vidal X, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): a cross-national drug utilization study. Br J Clin Pharmacol. 2019;85(11):2524–39.CrossRef
3.
Zurück zum Zitat Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2(4):499–509.CrossRef Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2(4):499–509.CrossRef
4.
Zurück zum Zitat Park J, Lee SR, Choi EK, et al. Effectiveness and safety of direct oral anticoagulant for secondary prevention in Asians with atrial fibrillation. J Clin Med. 2019;8(12). Park J, Lee SR, Choi EK, et al. Effectiveness and safety of direct oral anticoagulant for secondary prevention in Asians with atrial fibrillation. J Clin Med. 2019;8(12).
5.
Zurück zum Zitat Jong L, Koops M, Gout-Zwart JJ, et al. Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference. Neth J Med. 2018;76:426–30.PubMed Jong L, Koops M, Gout-Zwart JJ, et al. Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference. Neth J Med. 2018;76:426–30.PubMed
6.
Zurück zum Zitat Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767–76.CrossRef Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767–76.CrossRef
7.
Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRef Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRef
8.
Zurück zum Zitat Ng DL, Gan GG, Chai CS, et al. Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. Patient Prefer Adherence. 2019;13:1363–73.CrossRef Ng DL, Gan GG, Chai CS, et al. Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. Patient Prefer Adherence. 2019;13:1363–73.CrossRef
9.
Zurück zum Zitat Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRef Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRef
10.
Zurück zum Zitat Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549–58.CrossRef Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549–58.CrossRef
11.
Zurück zum Zitat Song Y, Wang X, Perlstein I, et al. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. Clin Ther. 2015;37(8):1703–12.CrossRef Song Y, Wang X, Perlstein I, et al. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. Clin Ther. 2015;37(8):1703–12.CrossRef
12.
Zurück zum Zitat Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476–87.CrossRef Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476–87.CrossRef
13.
Zurück zum Zitat Cada DJ, Levien TL, Baker DE. Apixaban. Hosp Pharm. 2013;48(6):494–509.CrossRef Cada DJ, Levien TL, Baker DE. Apixaban. Hosp Pharm. 2013;48(6):494–509.CrossRef
14.
Zurück zum Zitat Sharma G, Hanipah ZN, Aminian A, et al. Bariatric surgery in patients on chronic anticoagulation therapy. Obes Surg. 2018;28(8):2225–32.CrossRef Sharma G, Hanipah ZN, Aminian A, et al. Bariatric surgery in patients on chronic anticoagulation therapy. Obes Surg. 2018;28(8):2225–32.CrossRef
15.
Zurück zum Zitat Sherf-Dagan S, Goldenshluger A, Azran C, et al. Vitamin K–what is known regarding bariatric surgery patients: a systematic review. Surg Obes Relat Dis. 2019;15(8):1402–13.CrossRef Sherf-Dagan S, Goldenshluger A, Azran C, et al. Vitamin K–what is known regarding bariatric surgery patients: a systematic review. Surg Obes Relat Dis. 2019;15(8):1402–13.CrossRef
16.
Zurück zum Zitat Homan J, Ruinemans-Koerts J, Aarts EO. Management of vitamin K deficiency after biliopancreatic diversion with or without duodenal switch. Surg Obes Relat Dis. 2016;12(2):338–44.CrossRef Homan J, Ruinemans-Koerts J, Aarts EO. Management of vitamin K deficiency after biliopancreatic diversion with or without duodenal switch. Surg Obes Relat Dis. 2016;12(2):338–44.CrossRef
17.
Zurück zum Zitat Kido K, Lee JC, Hellwig T, Gulseth MP. Use of direct oral anticoagulants in morbidly obese patients. Pharmacotherapy. 2020;40(1):72–83.CrossRef Kido K, Lee JC, Hellwig T, Gulseth MP. Use of direct oral anticoagulants in morbidly obese patients. Pharmacotherapy. 2020;40(1):72–83.CrossRef
18.
Zurück zum Zitat Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908–16.CrossRef Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908–16.CrossRef
19.
Zurück zum Zitat Choi Y, Kushnir M, Billett HH. Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI ≥40. Blood. 2017;130(Supplement 1):1105. Choi Y, Kushnir M, Billett HH. Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI ≥40. Blood. 2017;130(Supplement 1):1105.
20.
Zurück zum Zitat Safouris A, Demulder A, Triantafyllou N, et al. Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. J Neurol Sci. 2014;346(1–2):366–7.CrossRef Safouris A, Demulder A, Triantafyllou N, et al. Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. J Neurol Sci. 2014;346(1–2):366–7.CrossRef
21.
Zurück zum Zitat Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218–26.CrossRef Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218–26.CrossRef
22.
Zurück zum Zitat Patil T, Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb Res. 2020;192:124–30.CrossRef Patil T, Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb Res. 2020;192:124–30.CrossRef
23.
Zurück zum Zitat Rottenstreich A, Barkai A, Arad A, et al. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb Res. 2018;163:190–5.CrossRef Rottenstreich A, Barkai A, Arad A, et al. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb Res. 2018;163:190–5.CrossRef
24.
Zurück zum Zitat Mahlmann A, Gehrisch S, Beyer-Westendorf J. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis. 2013;36(4):533–5.CrossRef Mahlmann A, Gehrisch S, Beyer-Westendorf J. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis. 2013;36(4):533–5.CrossRef
25.
Zurück zum Zitat Leven C, Hoffmann C, Roche C, et al. Impact of bariatric surgery on oral anticoagulants pharmacology, and consequences for clinical practice: a narrative review. Fundam Clin Pharmacol. 2021;35(1):53–61.CrossRef Leven C, Hoffmann C, Roche C, et al. Impact of bariatric surgery on oral anticoagulants pharmacology, and consequences for clinical practice: a narrative review. Fundam Clin Pharmacol. 2021;35(1):53–61.CrossRef
26.
Zurück zum Zitat Byon W, Garonzik S, Boyd RA, et al. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265–79.CrossRef Byon W, Garonzik S, Boyd RA, et al. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265–79.CrossRef
27.
Zurück zum Zitat Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J. 2014;12(1):22.CrossRef Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J. 2014;12(1):22.CrossRef
28.
Zurück zum Zitat Testa S, Paoletti O, Legnani C, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018;16(5):842–8.CrossRef Testa S, Paoletti O, Legnani C, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018;16(5):842–8.CrossRef
29.
Zurück zum Zitat Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. Surg Obes Relat Dis. 2018;14(12):1890–6.CrossRef Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. Surg Obes Relat Dis. 2018;14(12):1890–6.CrossRef
Metadaten
Titel
Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery
verfasst von
Thom Kok
Hans de Boer
Bart Witteman
Marcel Hovens
Matthijs van Luin
Houshang Monajemi
Publikationsdatum
25.11.2021
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 3/2022
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05814-y

Neu im Fachgebiet Chirurgie

Antibiotika bei Erwachsenen mit Appendizitis oft ausreichend

Bei etwa zwei Drittel aller Erwachsenen mit akuter Appendizitis könnte eine antibiotische Behandlung ausreichen, wie eine Metaanalyse nahelegt. Die Komplikationsrate war insgesamt gering, auch wenn letztlich doch eine Op. fällig wurde.

Katheterablation bei Vorhofflimmern: Ist frühe Intervention von Vorteil?

Bei Patienten mit Vorhofflimmern scheinen die Therapieergebnisse bezüglich Rezidivfreiheit bei frühzeitiger Katheterablation besser zu sein als bei später erfolgter Ablation. Dafür sprechen Ergebnisse einer aktuellen Registeranalyse. 

Beugt Tranexamsäure schweren Blutungen auch in der Allgemeinchirurgie vor?

Ergebnisse einer Subgruppenanalyse der POISE-3-Studie sprechen dafür, dass eine Prophylaxe mit Tranexamsäure auch bei allgemeinchirurgischen Eingriffen das Risiko für schwere Blutungen senkt.

Höhere Anspannung vor der Op. führt offenbar zu besserem Ergebnis

Ein gewisses Maß an Stress zu Beginn der Op. wirkt sich möglicherweise positiv auf das Gelingen aus, so ein Team aus Boston. Die Komplikationsrate ging unter diesen Umständen signifikant zurück.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.